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Abstract The imipenem and meropenem-resistant strains
Citrobacter freundii HS70 and Escherichia coli HS510
were isolated from patients in Shanghai, China. By
isoelectric focusing, PCR amplification and sequencing,
these strains were each found to produce four β-lactamases:
TEM-1, KPC-3, SHV-7 and CTX-M-14. A conjugation
experiment and plasmid restriction digestion revealed that
the blaKPC-3 gene was located on the same plasmid in both
isolates. Bidirectional primer walking sequencing showed
that the nucleotide sequence surrounding the 3.8 kb blaKPC-3
contained a 671-bp insertion similar to that previously
characterized in China. The insertion was located between
the promoter and the coding region of the blaKPC-3 gene.
Susceptibility testing performed on recombinant strains
carrying the blaKPC-3 gene with or without the insertion
revealed that minimum inhibitory concentrations of imipe-
nem, meropenem, cefepime, and cefotaxime for E. coli
EMU-KPC3 (without insertion) were four times higher than
that of E. coli EKPC3 (with insertion). The 671 bp insertion
reduced blaKPC-3 expression significantly. Taken together,
these results suggest that KPC-3-producing C. freundii and
E. coli have begun to emerge in our hospital.
Introduction
The extensive use of carbapenems has resulted in the
emergence of carbapenem-resistant Enterobacteriaceae
strains [4]. The resistance may be mediated by the
production of carbapenemases [15, 19], as well as AmpC
hyper-production combined with decreased outer mem-
brane permeability due to loss or alteration of porins [14].
The Ambler class A Klebsiella pneumoniae carbapenemase
(KPC) enzymes [13] are able to hydrolyze all known β-
lactam-containing molecules and are the most frequently
observed class A carbapenemases.
KPC-1, a plasmid encoded β-lactamase, was first
identified from K. pneumoniae in North Carolina (USA)
and is identical to the blaKPC-2 gene by sequencing [25, 26].
Strains harboring blaKPC-1/KPC-2 have also been isolated
from patients in France [9], Israel [12], South America [18],
Greece [3], and China [20]. The blaKPC-3 sequence
(GenBank AM774409) is found in the same genetic
environment as blaKPC-2 in Salmonella cubana 4707
(GenBank AF481906) [5], and this KPC enzyme is now
prevalent in America [22], Israel [6], and the United
Kingdom [23].
In this study, we identified strains of Citrobacter freundii
and E. coli isolated from Chinese patients that express
KPC-3. The background of the blaKPC-3 gene was different
from that reported outside of China and it was similar to
that reported in China previously [27].
Materials and methods
Bacterial strains and plasmids
The imipenem and meropenem-resistant strain C. freundii
HS70 was isolated from the urine of a 53-year-old female
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The imipenem and meropenem-resistant strain E. coli
HS510 was isolated from urine of a 59-year-old female
inpatient at the same hospital. Both strains were identified
by Vitek-32 (BioMerieux, Marcy, France). E. coli J53 was
used as a recipient in conjugal mating experiments, whereas
E. coli DH5α was used for cloning. Other derivative strains
and plasmids used in this study are listed in Table 1.
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) for organisms
were determined by the Mueller-Hinton (M-H) agar
dilution method according to guidelines of the Clinical
and Laboratory Standards Institute [2]. Antimicrobial
agents evaluated included imipenem, meropenem, cefepime,
cefotaxime, ampicillin, ciprofloxacin, and gentamicin. All
were obtained from Oxoid (Basingstoke, England). E. coli
ATCC25922 was used for quality control.
Conjugation experiments and plasmid restriction enzyme
digestion analysis
Transfer of imipenem resistance was studied by performing
conjugation experiments as previously described [24]w i t hE.
coli J53 as the recipient. Transconjugants were selected from
agar plates supplemented with sodium azide (100 μg/mL;
Oxoid, Basingstoke, England) and ceftazidime (2 μg/mL;
Oxoid, Basingstoke, England), and identified by VITEK-32.
For the plasmid restriction enzyme analysis, XbaI and ClaI
(Takara, Dalian, China) were used. Digested plasmid DNA
samples from transconjugants were then analyzed by
electrophoresis on 0.6% agarose gels at a constant voltage
of 100 V for 0.5 h.
Isoelectric focusing of β-lactamases
Crude cell lysates were prepared by a previously described
freeze–thaw procedure [17]. Isoelectric focusing was
performed as described by Matthew and Harris [8]. Cell
extracts were loaded onto prepared polyacrylamide gel
plates (pH 3 to 9; Amersham Biosciences, Uppsala,
Sweden) and electrophoresed to equilibrium using Pharma-
cia PhastSystem (Uppsala, Sweden). β-lactamases were
then visualized by staining the gel with a 0.05% solution of
nitrocefin (BD Biosciences, San Jose, CA, USA). The
isoelectric points of TEM-1, KPC-3, SHV-7 and CTX-M-
14 were determined by comparison to known pIs of the β-
lactamases (TEM-12, pI 5.25; TEM-28, pI 6.1; SHV-7, pI
7.6; and ACT-1, pI 9.0).
PCR analysis and nucleotide sequencing
Crude genomic DNAwas extracted from the isolates by heat
lysis. β-lactamase genes were identified by PCR with specific
primers designed to sequences of known β-lactamase genes,
including blaTEM, blaSHV, blaKPC, blaCTX-M-1, blaCTX-M-9,
and blaCTX-M-2.F o rP C R st h eLA Taq DNA polymerase
(Takara, Dalian, China) was used according to the manu-
facturer’s instructions. Primer sequences are listed in Table 2.
Strains or plasmids Description Reference
Plasmids
pACYC184 Cloning vector
pacyc184-KPC3 Insertion of 727-2902 region between BamHI
and EcoRI restriction site in pACYC184
FJ609231
pMU-acyc184-KPC3 Deletion of 1188-1706 in pacyc184-KPC3 FJ609231
pHS70 Plasmid from E. coli J 53 (pHS70) This study
pHS510 Plasmid from E. coli J 53 (PhS510) This study
Strains
Citrobacter freundii
HS70 Clinical isolate This study
E. coli
HS510 Clinical isolate This study
E. coli J 53 (pHS70) E. coli J53 transconjugant derived from HS70 This study
E. coli J 53 (pHS510) E. coli J53 transconjugant derived from HS510 This study
EKPC3 E. coli DH5a containing pacyc184-KPC3 This study
EMU-KPC3 E. coli DH5a containing pMU-acyc184-KPC3 This study
DH5α E. coli reference lab strain
J53 E. coli reference lab strain
ATCC25922 E. coli reference lab strain
Table 1 Bacterial strains and
plasmids used in this study
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then sequenced by an ABI 3730 analyzer, and the obtained
sequences were aligned with sequence data from GenBank.
Analysis of the genetic environment of the blaKPC-3 gene
and plasmid construction
The genetic context of the blaKPC-3 gene was examined by
bidirectional primer walking sequencing, performed on
plasmids from transconjugants using primers designed
previously [20]. The obtained sequence was aligned with
β-lactamase sequences from the GenBank database using
the BLAST program. Primers KPC-3 F and KPC-3R were
used to amplify the DNA fragments, which included the
entire blaKPC gene and the region flanking the insertion in
the plasmid isolated from the Chinese patients. The
obtained PCR products and plasmid pACYC184 were
digested using Bam HI and EcoRI, then ligated using T4
DNA ligase. The obtained plasmid pACYC184-KPC3 was
electroporated into E. coli DH5α. Clones were selected on
Luria-Bertani agar plates containing chloramphenicol
(40 mg/mL) and imipenem (1.5 mg/mL). Primers MU-
KPC-3F and MU-KPC-3R were designed to amplify the
whole recombinant plasmid pACYC184-KPC3 without the
671 bp insertion fragment. The obtained PCR products
were ligated by using a MutantBEST kit (Takara) to
produce the plasmid pMU-ACYC184-KPC3. The recombi-
nant plasmids pACYC184-KPC3 (with insertion) and
pMU-ACYC184-KPC3 (without insertion) were then indi-
vidually transformed into E. coli DH5α by the calcium
phosphate method.
Results
Antimicrobial resistance
E. coli HS510 was isolated from the urine of a 59-year-old
female patient and was found resistant to imipenem and
meropenem, with a MIC of 16 μg/mL for both antibiotics.
C. freundii HS70 was isolated from the urine of a 53-year-
old female patient and had a MIC of ≥128 μg/mL for both
antibiotics (Table 3).
Isoelectric focusing and PCR analysis of β-lactamases
In order to understand the antimicrobial resistant pheno-
type, β-lactamases were analyzed by isoelectric focusing,
PCR and PCR product sequencing. Isoelectric focusing of
clinical isolates revealed that both E. coli HS510 and C.
freundii HS70 produced four β-lactamases which possess
pIs of 5.4, 6.7, 7.6, and 8.1 (Fig. 1), respectively. To
determine which lactamases they were, PCR was performed
on DNA from the clinical isolates with primers specific for
KPC, TEM, SHV, CTX-M-1, CTX-M-2, and CTX-M-9.
Sequencing analysis of two clinical isolates confirmed that
both E. coli HS510 and C. freundii HS70 carried blaTEM-1,
blaCTX-M-14, blaSHV-7 and blaKPC-3.
Table 2 Primers for PCR amplification of the β-lactamases genes and for cloning
ESBL or plasmid Primer Sequence Position GenBank accession
number or reference
KPC KPC-F 5′-ATGTCACTGTATCGCCGTCT-3′ 131-150 AF297554
KPC-R 5′-TTTTCAGAGCCTTACTGCCC-3′ 1023-1042
TEM TEM-F 5′-ATAAAATTCTTGAAGAC-3′ 1–17 X54604.1
TEM-R 5′-TTACCAATGCTTAATCA-3′ 1075–1059
SHV SHV-F 5′-TGGTTATGCGTTATATTCGCC-3 69–89 X98100.1
SHV-R 5′-GCTTAGCGTTGCCAGTGCT-3′ 936–918
CTX-M-1 M1F 5′- GGTTAAAAAATCACTGCGTC -3 65–84 X92506
M1 R 5′- TTGGTGACGATTTTAGCCGC-3 928–909
CTX-M-9 M9F 5′-ATGGTGACAAAGAGAGTGCA-3 1–20 AF252621.2
M9R 5′-CCCTTCGGCGATGATTCTC-3′ 870–852
M2F 5′-ATGATGACTCAGAGCATTCG-3′ 304–323
CTX-M-2 M2R 5′-TGGGTTACGATTTTCGCCGC-3′ 1169–1150 AJ416343.1
pacyc184-KPC3 KPC-3 F 5′-GCCTGGTCCGAATTCCCTCGTCATCCGCAGACCAAC-3′ 727-747 FJ609231
KPC-3R 5′-GCCTGGTCCGGATCCCGCGCAGACTCCTAGCCTAAA-3′ 2882-2902
pMU-acyc184-KPC3 MU-KPC-3 F 5′-CTTAACGTGAGTTTTCGTTCCACTGAGCG-3′ 1816-1844 FJ609231
MU-KPC-3R 5′-AAGTCATTTTTCAATATTATTGAAGCATTT ATC-3′ 1112-1144
ESBL extended-spectrum beta-lactamase
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Conjugation experiments successfully transferred a plasmid
from both clinical isolates to the recipient E. coli J53. In
order to understand which resistant genes can be transferred
by plasmid conjugation, we used PCR to identify every β-
lactamase gene that the two clinical isolates contained on
transconjugants. PCR results confirmed that both transconju-
gants only carried the blaKPC-3 gene. Restriction enzyme
(XbaI and ClaI) digestion of plasmids from transconjugants
showed that they had identical enzyme digestion maps
(Fig. 2). Our results indicated that the blaKPC gene was
located on the same plasmid in both clinical isolates.
Characterization of the genetic environment
of the blaKPC-3 gene
Bidirectional primer walking performed on transconjugated
plasmids produced a 3,850 bp fragment. The nucleotide
Table 3 Antimicrobial susceptibility patterns
a
Antimicrobial agent(s) MIC (μg/mL)
HS70
b E. coli J 53(pHS70) HS510 E. coli J 53(pHS510) EKPC3 EMU-KPC3 25922
c
Imipenem ≥128 2 16 2 8 32 ≤0.0625
Meropenem ≥128 2 16 2 8 32 ≤0.0625
Cefepime ≥128 8 64 8 16 64 ≤0.0625
Cefotaxime ≥128 16 ≥128 16 16 64 ≤0.0625
Ampicillin ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 2
Ciprofloxacin ≥128 ≤0.0625 ≥128 ≤0.0625 ≤0.0625 ≤0.0625 ≤0.0625
Gentamicin ≥128 ≤0.0625 ≥128 ≤0.0625 ≤0.0625 ≤0.0625 ≤0.0625
a Minimum inhibitory concentrations (MICs) were determined by the M-H agar dilution method according to guidelines of the Clinical and Laboratory
Standards Institute
b Clinical isolates: E. coli HS510 and C. freundii HS70. Transconjugants: E. coli J 53 (pHS510); E. coli J 53 (pHS70). Recombinants: EKPC3, E. coli
DH5a/ pacyc184-KPC3; EMU-KPC3, E. coli DH5a/ pMU-acyc184-KPC3. Lab reference E. coli strain: 25922
c E. coli ATCC 25922 was used as quality control of antimicrobial susceptibility testing
Fig. 1 Isoelectric focusing
patterns of clinical isolates E. coli
HS510 and C. freundii HS70.
Lane 1: Cell lysate prepared from
C. freundii HS70 producing
TEM-1 (pI 5.4), KPC-3 (pI 6.7),
SHV-12 (pI 7.6), and CTX-M-14
(pI 7.9). Lane 2: Cell lysate
prepared from E. coli HS510
producing TEM-1, KPC-3,
SHV-12 and CTX-M-14
Fig. 2 Electrophoretic analysis of XbaI- and ClaI-digested plasmids.
Lane 2: E. coli transconjugants of HS70. Lane 3: E. coli trans-
conjugants of HS510. Marker lane: 100-bp and 1-Kb DNA ladders
(Takara)
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FJ609231. Sequence alignment showed that the FJ609231
sequence was similar to AM774409.1. FJ609231 carried
the blaKPC-3 gene; EU176014.1 and FJ628167 each carried
a blaKPC-2 gene. Furthermore, FJ609231 showed a similar
structure and context with FJ628167, except for a 671-bp
fragment insertion between the blaKPC-3 promoter and the
blaKPC coding region (between positions 20571 and 20572
of FJ628167; see Fig. 3). As for FJ628167, an ISKpn6-like
element is located downstream of the blaKPC-3 gene and a
Tn3 transposon and ISKpn8 is located upstream of the
blaKPC-3 gene [27]. The additional 671 bp insertion looks
like a piece of TEM1. The nucleotide sequence area is from
982 to 1928 of FJ609231, and looks like a rearranged
FJ223605.1.
Antimicrobial susceptibility testing of recombinants
To investigate the effects of the inserted 671-bp fragment
on blaKPC-3 expression, plasmids pKPC3-184 and pMU-
KPC3-184 were constructed using the vector pACYC184.
The plasmid pKPC3-184 was derived from plasmid pHS70,
and pMU-KPC3-184 was derived from plasmid pKPC3-
184. The genetic environment of the blaKPC gene on
pKPC3-184 was the same with pHS70. The genetic
environment of the blaKPC gene on pMU-KPC3-184 was
the same with pHS70 except for a 671-bp fragment
insertion between the blaKPC-3 promoter and the blaKPC
coding region. Recombinants E. coli EKPC3 and E. coli
EMU-KPC3 (with plasmids pKPC3-184 and pMU-KPC3-
184, respectively) were constructed and tested for antimi-
crobial susceptibility. The MICs of E. coli EMU-KPC3 for
imipenem and meropenem were four times higher than that
of E. coli EKPC3 (32 μg/mL vs. 8 μg/mL) as were MICs
for cefepime and cefotaxime (64 μg/mL for E. coli EMU-
KPC3 vs. 16 μg/mL for E. coli EKPC3), implying that the
671-bp fragment insertion decreased KPC-3 expression.
Discussion
This is the first time that the blaKPC-3 gene was reported in
China. Nine KPC variants have so far been described
(KPC-2 to KPC-10; KPC-1 and KPC-2 are identical) in
different parts of the world; variants of KPC-1/2 differ by,
at most, two amino acid substitutions [1, 5, 6, 16, 21, 22].
The emergence of KPC-type carbapenem-hydrolyzing
enzymes is alarming. E. coli transconjugants carrying the
blaKPC-3 gene from either clinical isolate in our study had
MICs of 2 μg/mL for both imipenem and meropenem.
Additional mechanisms must underlie the drug resistance of
clinical isolates C. freundii HS70 and E. coli HS510 since
their MICs for imipenem and meropenem were greater than
that of their E. coli transconjugants. Previous reports showed
that the lost porins OmpK36 and OmpK35 are perhaps
associated with the increase in MICs for carbapenems [22].
Our conjugation experiments, plasmid restriction enzyme
digestion analysis and PCR of the β-lactamase gene con-
firmed that blaKPC-3 from both clinical isolates is located on
the same conjugational plasmid. Sequence analysis revealed
that 3.8 Kb of DNA sequence surrounding the blaKPC-3 gene
of these two isolates was also the same, and its construction
was similar to AM774409.1 from Enterobacter cloacae and
EU176014.1 from Klebsiella pneumoniae. It was composed
of ISKpn8,t h eblaKPC-3 promoter, a 671-bp insertion, the
blaKPC-3 gene and an ISkpn6-like element (Fig. 3). This
DNA fragment is one part of a Tn3-based transposon,
Tn4401, which is likely to be the origin of blaKPC
mobilization and further insertion into various plasmids of
non-clonally related organisms [10].
This report provides further confirmation of the puta-
tively transposable element found on plasmids of K.
pneumoniae and P. aeruginosa that may be responsible
for the rapid global dissemination of this gene. The region
upstream of the blaKPC-3 identified here differs from
AM774409.1 and EU176014.1 (Fig. 3). A 671-bp fragment
insertion was found between the blaKPC-3 promoter and the
blaKPC-3 coding region (between positions 20571 and
20572 of FJ628167). This finding confirms Naas’s propo-
sition [10] that this region of the element is unstable, and
suggests that other isoforms of Tn4401 do exist. Naas et al.
identified a 100-bp deletion upstream of blaKPC from two
clinical strains of K. pneumonia, namely, GR and YC [10].
Interestingly, we found that the insertion decreased
blaKPC-3 expression. Our results provide important infor-
mation on the genetic environment of blaKPC-3 genes
identified in clinical isolates in China and the significance
of blaKPC-3 in this genetic context warrants further study.
Fig. 3 Schematic representation of novel genetic structure involved in
blaKPC-3 gene found in bacteria isolated from Chinese patients.
EU176014.1 contains ISKpn7, blaKPC-3 and ISKpn6; AM774409.1
contains ISKpn7, blaKPC-2 and ISKpn6; FJ628167 contains ISKpn8,
blaKPC-2 and an ISKpn6-like element; this study contained ISKpn8,
truncated β-latamase, blaKPC-3 and an ISKpn6-like element
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